Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS | Aplastic Anemia & MDS International Foundation
Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS

Clinical Trial: NCT02969980

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This study is conducted to evaluate the feasibility and efficacy of post-transplantation cyclophosphamide with myeloablative or reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS).

Status: 
Recruiting
Study Date: 
Mon, 11/21/2016 to Mon, 11/30/2020
Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: Cyclophosphamide Cyclophosphamide 25 mg/kg/day i.v. daily on days 3 and 4 of hematopoietic cell transplantation